West Pharmaceutical Services, Inc.
WST · NYSE
WST · NYSE
West Pharmaceutical Services designs and manufactures packaging components and delivery systems for injectable medicines, selling to pharmaceutical and biotech manufacturers. Its business includes proprietary products, including high-value components used in biologics and GLP-1 therapies, and contract-manufactured products and devices; the supplied evidence does not quantify their revenue shares. West Vantage and SmartDose also feature in the company’s business discussions, although the evidence gives no sales contribution for either. Customers use its products and systems to package and administer injectable drugs. West reported FY2025 revenue of $3.1 billion and net income of $0.5 billion, compared with FY2024 revenue of $2.9 billion and net income of $0.5 billion.
WST gained 5.22%, rising from $392.15 to $412.62 over the supplied week. Shares climbed through Wednesday and advanced to $416.67 on Thursday, October 29, when West reported third-quarter results above expectations and raised its 2026 outlook. The results included $874.5 million in sales, up 8.7% year over year, and management cited demand for high-value products used in biologics and GLP-1 therapies. The stock then gave back $4.05 on Friday, closing at $412.62, but retained most of its earlier advance. The supplied evidence points to the earnings beat and higher guidance as the principal company-specific catalysts.
